Cargando…

Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy

PURPOSE: The purpose of this study was to evaluate if HPV status serves as an independent predictor of early and late dysphagia outcomes when considered alongside standard patient characteristics and dose metrics for head and neck cancer patients treated with radiotherapy. METHODS AND MATERIALS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Xenia, Sumner, Whitney, Sutton, Leisa, Sanghvi, Parag, Deichaite, Ida, Moiseenko, Vitali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425061/
https://www.ncbi.nlm.nih.gov/pubmed/34493300
http://dx.doi.org/10.1186/s12967-021-03047-2
_version_ 1783749782358982656
author Ray, Xenia
Sumner, Whitney
Sutton, Leisa
Sanghvi, Parag
Deichaite, Ida
Moiseenko, Vitali
author_facet Ray, Xenia
Sumner, Whitney
Sutton, Leisa
Sanghvi, Parag
Deichaite, Ida
Moiseenko, Vitali
author_sort Ray, Xenia
collection PubMed
description PURPOSE: The purpose of this study was to evaluate if HPV status serves as an independent predictor of early and late dysphagia outcomes when considered alongside standard patient characteristics and dose metrics for head and neck cancer patients treated with radiotherapy. METHODS AND MATERIALS: The age, sex, smoking history, cancer type (oropharyngeal vs non-oropharyngeal), HPV status, and early and late dysphagia outcomes were obtained for 99 retrospective head and neck cancer patients treated at our clinic with radiotherapy. Additionally for each patient, the mean radiation dose to the pharynx, superior/middle/inferior pharyngeal constrictor muscles, and cricopharyngeus was calculated. The predictive power of these clinical characteristics and radiation metrics was evaluated using chi-square tests for categorical variables and t-tests for continuous variables. Then multi-variate logistic models were built for each outcome using a single dose metric at a time, and either HPV status, cancer type, or both. Multi-variate models were built using both top-down and bottom-up technique to establish the most predictive independent covariates. RESULTS: In the univariate analysis for early dysphagia, cancer type (p = 0.04) and four dose metrics (p ≤ 0.02) were significantly associated with outcome, while for late dysphagia, only cancer type (p = 0.04) was associated with outcome. In the multivariate analysis for early dysphagia, cancer type, smoking history, and mean dose to the five structures were consistently selected as covariates. For late dysphagia, either HPV status or cancer type was selected in each model and the mean dose to the cricopharyngeus was selected in one model. CONCLUSION: While HPV is a known contributing factor for tumor prognosis in oropharyngeal cancers, its role in normal tissue toxicities for head and neck cancers has not previously been evaluated. Our results indicate having an oropharyngeal cancer may increase a patient’s risk of high-grade early and late dysphagia while HPV status was seldom selected.
format Online
Article
Text
id pubmed-8425061
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84250612021-09-10 Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy Ray, Xenia Sumner, Whitney Sutton, Leisa Sanghvi, Parag Deichaite, Ida Moiseenko, Vitali J Transl Med Research PURPOSE: The purpose of this study was to evaluate if HPV status serves as an independent predictor of early and late dysphagia outcomes when considered alongside standard patient characteristics and dose metrics for head and neck cancer patients treated with radiotherapy. METHODS AND MATERIALS: The age, sex, smoking history, cancer type (oropharyngeal vs non-oropharyngeal), HPV status, and early and late dysphagia outcomes were obtained for 99 retrospective head and neck cancer patients treated at our clinic with radiotherapy. Additionally for each patient, the mean radiation dose to the pharynx, superior/middle/inferior pharyngeal constrictor muscles, and cricopharyngeus was calculated. The predictive power of these clinical characteristics and radiation metrics was evaluated using chi-square tests for categorical variables and t-tests for continuous variables. Then multi-variate logistic models were built for each outcome using a single dose metric at a time, and either HPV status, cancer type, or both. Multi-variate models were built using both top-down and bottom-up technique to establish the most predictive independent covariates. RESULTS: In the univariate analysis for early dysphagia, cancer type (p = 0.04) and four dose metrics (p ≤ 0.02) were significantly associated with outcome, while for late dysphagia, only cancer type (p = 0.04) was associated with outcome. In the multivariate analysis for early dysphagia, cancer type, smoking history, and mean dose to the five structures were consistently selected as covariates. For late dysphagia, either HPV status or cancer type was selected in each model and the mean dose to the cricopharyngeus was selected in one model. CONCLUSION: While HPV is a known contributing factor for tumor prognosis in oropharyngeal cancers, its role in normal tissue toxicities for head and neck cancers has not previously been evaluated. Our results indicate having an oropharyngeal cancer may increase a patient’s risk of high-grade early and late dysphagia while HPV status was seldom selected. BioMed Central 2021-09-07 /pmc/articles/PMC8425061/ /pubmed/34493300 http://dx.doi.org/10.1186/s12967-021-03047-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ray, Xenia
Sumner, Whitney
Sutton, Leisa
Sanghvi, Parag
Deichaite, Ida
Moiseenko, Vitali
Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title_full Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title_fullStr Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title_full_unstemmed Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title_short Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
title_sort evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425061/
https://www.ncbi.nlm.nih.gov/pubmed/34493300
http://dx.doi.org/10.1186/s12967-021-03047-2
work_keys_str_mv AT rayxenia evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy
AT sumnerwhitney evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy
AT suttonleisa evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy
AT sanghviparag evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy
AT deichaiteida evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy
AT moiseenkovitali evaluatingpredictivefactorsfortoxicitiesexperiencedbyheadneckcancerpatientsundergoingradiotherapy